DDInter899 DDInter1623
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection.
Rotavirus vaccine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Budesonide
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Carmustine
Rotavirus vaccine {u} may lead to a major life threatening interaction when taken with {v} Sarilumab
Rotavirus vaccine may cause a moderate interaction that could exacerbate diseases when taken with Budesonide
Rotavirus vaccine may lead to a major life threatening interaction when taken with Carmustine
Rotavirus vaccine may lead to a major life threatening interaction when taken with Sarilumab